Sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (MIBC): The phase 2, SASAN-SPARING trial.

Authors: Elena Sevillano, Julia Martinez Perez, Nuria Lainez Milagro, Pablo Gajate Borau, Xavier Garcia del Muro, Javier Puente, Miguel Angel Climent, Alfonso Gomez de LiaƱo, Oscar Reig Torras, Guillermo de Velasco

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4626

Source: Full article


Abstract

TPS4626